Overview

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: - Disease related quality-of-life - Exercise capacity - Renal function - Concomitant medications
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
Adenosine
Adenosine A1 Receptor Antagonists